Valuation: Decoy Therapeutics Inc.

Market Cap 8L 7L 6L 6L 10.84L 7.28Cr 11.02L 75.92L 29.76L 3.8Cr 28.77L 28.16L 12Cr P/E 2026 *
-0.13x
P/E 2027 * -0.14x
Enterprise Value 8L 7L 6L 6L 10.84L 7.28Cr 11.02L 75.92L 29.76L 3.8Cr 28.77L 28.16L 12Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.57%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Decoy Therapeutics Inc.

1 day-4.88%
1 week-20.41%
Current month-40.61%
1 month-59.52%
3 months-80.47%
6 months-80.07%
Current year-84.97%
1 week 1.15
Extreme 1.15
1.49
1 month 1.15
Extreme 1.15
7.61
Current year 1.15
Extreme 1.15
16.92
1 year 1.15
Extreme 1.15
50.6
3 years 1.15
Extreme 1.15
1,339.2
5 years 1.15
Extreme 1.15
35,459.97
10 years 1.15
Extreme 1.15
5,33,353.97
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Free

Founder

33,455 5.1062%
31/08/26 Free

Chief Financial Officer

9,682 1.4778%
31/08/26 Free

Director

2,000 0.3053%
Change 5-day change 1-year change 3-year change Capi.($)
-4.88%-20.41%-97.71%-99.88% 8L
-6.60%-8.56%+42.79%+64.16% 6.9TCr
-4.09%-0.11%+2.31%+54.81% 5.31TCr
+0.03%+5.56%+10.18%+41.75% 5.08TCr
-1.53%+2.70%+29.72%+34.13% 4.46TCr
-1.34%+4.12%+16.05%+112.18% 4.25TCr
-5.97%-6.22%+258.21%+421.57% 4.06TCr
+6.53%+8.02%+15.74%+53.94% 3.09TCr
-0.90%-10.49%+31.48%-1.63% 2.54TCr
-2.76%-9.54%-16.53%-9.55% 2.27TCr
Average -2.15%-2.25%+29.22%+67.15% 3.8TCr
Weighted average by Cap. -2.43%-0.10%+44.74%+90.25%

Financials

2026 *2027 *
Net sales - -
Net income -1.01Cr -89.78L -83.21L -75.71L -1.43Cr -96Cr -1.45Cr -10Cr -3.92Cr -50Cr -3.79Cr -3.71Cr -159.46Cr -1.91Cr -1.7Cr -1.57Cr -1.43Cr -2.7Cr -181.27Cr -2.75Cr -19Cr -7.42Cr -95Cr -7.17Cr -7.02Cr -301.56Cr
Net Debt - -
Projected Income Statement - Annual - Decoy Therapeutics Inc.
Logo Decoy Therapeutics Inc.
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Employees
11
Date Price Change Volume
16/26/16 $1.170 -4.88% 37,400
15/26/15 $1.230 +5.13% 90,315
14/26/14 $1.170 -5.65% 89,864
13/26/13 $1.240 -13.29% 1,67,666
12/26/12 $1.430 -2.72% 59,045
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.170USD
Average target price
3.000USD
Spread / Average Target
+156.41%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Decoy Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. DCOY Stock